<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>In This Issue/Research Watch/News in Brief</td>
<td>167</td>
</tr>
<tr>
<td>From the IASLC Tobacco Control Committee</td>
<td>173</td>
</tr>
<tr>
<td><strong>EDITORIALS</strong></td>
<td></td>
</tr>
<tr>
<td>Programmed Cell Death Protein-1/Programmed</td>
<td>176</td>
</tr>
<tr>
<td>Death-Ligand 1 Inhibitors in NSCLC: Two</td>
<td></td>
</tr>
<tr>
<td>Heads Are Better Than One</td>
<td></td>
</tr>
<tr>
<td>Yen-Ting Lin, MD, and Jin-Yuan Shih, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Chemoimmunotherapy for EGFR-Mutant NSCLC:</td>
<td>179</td>
</tr>
<tr>
<td>Still No Clear</td>
<td></td>
</tr>
<tr>
<td>Bharathi Muthusamy, MD, and Nathan Pennell,</td>
<td></td>
</tr>
<tr>
<td>MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Targeting Alternative Splicing as Adjunctive</td>
<td>182</td>
</tr>
<tr>
<td>Treatment in EML4-ALK v3a/b+ NSCLC:</td>
<td></td>
</tr>
<tr>
<td>Knowing Our Socratic Paradox and Learning</td>
<td></td>
</tr>
<tr>
<td>From Spinal Muscular Atrophy</td>
<td></td>
</tr>
<tr>
<td>Misako Nagasaka, MD, PhD, and Sai-Hong</td>
<td></td>
</tr>
<tr>
<td>Ignatius Ou, MD, PhD</td>
<td></td>
</tr>
</tbody>
</table>

About the Cover: the cover image is from Figure 1 in the article by Rolfo on page 214.
EDITORIAL: LUNG CANCER WORLDWIDE

Lung Cancer in the United Kingdom.............................................................. 186
Neal Navani, MA, MSc, PhD, FRCP, David R. Baldwin, MD, FRCP,
John G. Edwards, PhD, FRCS, Matthew Evison, MD, MRCP,
Fiona McDonald, MD, FRCR, Andrew G. Nicholson, MD, FRCPath,
Jackie Fenemore, RN, MSc, Elizabeth K. Sage, PhD, MRCP, and Sanjay Popat, PhD, FRCP

CONTROVERSIES IN THORACIC ONCOLOGY

Postoperative Radiation Therapy Should Be Used for Completely Resected
Stage III-N2 NSCLC in Select Patients .......................................................... 194
Jason Liu, MD, Colton Ladbury, MD, Jae Kim, MD, Dan Raz, MD, PhD,
Loretta Erhunmwunsee, MD, Howard (Jack) West, MD, Terence Williams, MD, PhD,
Ravi Salgia, MD, PhD, Erminia Massarelli, MD, PhD, and Arya Amini, MD

Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage
III-N2 NSCLC.................................................................................................... 197
Corinne Faivre-Finn, MD, PhD, FRCR, John G. Edwards, MBChB., PhD, FRCS (C-Th),
and Matthew Hatton, MBChB., MSc, FRCP, FRCR

STATE OF THE ART: CONCISE REVIEW

OPEN ACCESS The 2021 WHO Classification of Tumors of the Thymus and
Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and
Mesenchymal Tumors? ............................................................... 200
Alexander Marx, MD, John K. C. Chan, MD, Lara Chalabreysse, MD,
Sanja Dacic, MD, PhD, Frank Detterbeck, MD, Christopher A. French, MD,
Jason L. Hornick, MD, PhD, Hiroshi Inagaki, MD, PhD, Deepali Jain, MD,
Alexander J. Lazar, MD, PhD, Mirella Marino, MD, Edith M. Marom, MD,
Andre L. Moreira, MD, PhD, Andrew G. Nicholson, MD, Masayuki Noguchi, MD,
Daisuke Nonaka, MD, Mauro G. Papotti, MD, Stefan Porubsky, MD,
Lynette M. Sholl, MD, Hisashi Tateyama, MD, Vincent Thomas de Montpréville, MD,
William D. Travis, MD, Arun Rajan, MD, Anja C. Roden, MD, and Philipp Ströbel, MD

SARS-CoV-2 Collection

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection:
Identifying Important Knowledge Gaps for Investigation......................... 214
Christian Rolfo, PhD, MD, MBA, Drhc, Noy Meshulami, BSc,
Alessandro Russo, MD, PhD, Florian Krammer, PhD, Adolfo García-Sastre, MD, PhD,
Philip C. Mack, PhD, Jorge E. Gomez, MD, Nina Bhardwaj, MD, PhD,
Amin Benyounes, MD, Rafael Sirera, MD, PhD, Amy Moore, PhD, Nicholas Rohs, MD,
Claudia I. Henschke, MD, PhD, David Yankelevitz, MD, Jennifer King, PhD,
Yu Shyr, MD, PhD, Paul A. Bunn Jr., MD, PhD, John D. Minna, MD, PhD, and
Fred R. Hirsch, MD, PhD, FASCO

(continued on next page)
ORIGINAL ARTICLES

SARS-CoV-2 Collection

Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report ........................................228
Rudolf M. Huber, MD, PhD, Milena Cavic, PhD, Anna Kerpel-Fronius, MD, Lucia Viola, MD, John Field, MD, PhD, Long Jiang, MD, PhD, Ella A. Kazerooni, MD, Coenraad F. N. Koegelenberg, MD, Anant Mohan, MD, PhD, Ricardo Sales dos Santos, MD, PhD, Luigi Ventura, MD, Murry Wynes, PhD, Dawei Yang, MD, Javier Zulueta, MD, Choon-Taek Lee, MD, PhD, Martin C. Tammemägi, PhD, Claudia I. Henschke, MD, and Stephen Lam, MD, for the members of the Diagnostics Working Group, Early Detection and Screening Committee

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses ... 239
Valérie Gounant, MD, MSc, Valentine Marie Ferré, PharmD, MSc, Ghassen Soussi, MD, Charlotte Charpentier, PharmD, PhD, Hélène Flamant, PharmD, PhD, Nadhira Fidouh, PharmD, Gilles Collin, MSc, Céline Namour, MSc, Sandra Assoun, MD, MSc, Alexandra Bizot, MD, MSc, Zohra Brouk, PhD, Eric Vicaut, MD, PhD, Luis Teixeira, MD, PhD, Diane Descamps, MD, PhD, and Gérard Zalcman, MD, PhD

Screening

Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks ................................................. 252
Hilary A. Robbins, PhD, Li C. Cheung, PhD, Anil K. Chaturvedi, PhD, David R. Baldwin, MD, FRCP, Christine D. Berg, MD, and Hormuzd A. Katki, PhD

Translational Oncology

Open Access Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC ... 264
Zhengbo Song, MD, PhD, Shifeng Lian, MD, MSc, Silvia Mak, MSc, Maggie Zi-Ying Chow, PhD, Chunwei Xu, MD, Wenhao Wang, MD, Hoi Yee Keung, PhD, Chengu Lu, MSc, Firaol Tamiru Kebede, PhD, Yanqiu Gao, BSc, Wah Cheuk, MD, PhD, William Chi Shing Cho, PhD, Mengsu Yang, PhD, and Zongli Zheng, PhD

Open Access Lung Cancer Driven by BRAFV600E Mutation Is Targetable by EGFR Kinase Inhibitors ............................................................................ 277
Ku-Geng Huo, PhD, Hirotsugu Notsuda, MD, PhD, Zhenhao Fang, PhD, Ningdi Feng Liu, BScH, Teklab Gebregiorgis, PhD, Quan Li, PhD, Nhu-An Pham, PhD, Ming Li, MD, Ni Liu, MSc, Frances A. Shepherd, MD, Christopher B. Marshall, PhD, Mitsuhiko Ikura, PhD, Nadeem Moghal, PhD, and Ming-Sound Tsao, MD, FRCP

(continued on next page)
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? .................................................................e10
Valerio Nardone, MD, Pierpaolo Correale, MD, Luciano Mutti, MD, Isacco Desideri, MD, Caterina Romeo, MD, Pierpaolo Pastina, MD, Piersandrea Tagliaferri, MD, Michele Caraglia, MD, Alfonso Reginelli, MD, Luigi Pirtoli, MD, and Salvatore Cappabianca, MD

In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?” ...........................................................................................................e12
Nicholas J. Thomas, BA, Nathaniel J. Myall, MD, Fangdi Sun, MD, Tejas Patil, MD, Rao Mushtaq, MD, Chandler Yu, BS, Sumi Sinha, MD, Eriq L. Pollom, MD, Seema Nagpal, MD, D. Ross Camidge, MD, PhD, Chad G. Rusthoven, MD, Steve E. Braunstein, MD, PhD, Heather A. Wakelec, MD, and Caroline E. McCoach, MD, PhD

Survival Analysis of TP53 Mutations Should Be Interpreted More Cautiously.............................................................................................................e14
Anqi Lin, BM, Peng Luo, BM, and Jian Zhang, PhD

Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed ...........................................................................................................e18
Fangqiu Fu, MD, Yang Zhang, MD, Na He, PhD, and Haiquan Chen, MD, PhD

Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated—A Response to Letter to the Editor........................................... e20
Anna Kerpel-Fronius, MD, Martin C. Tammemägi, DVM, MSc, PhD, Milena Cavic, PhD, and Rudolf M. Huber, Prof, MD, For the members of the Diagnostics Working Group, ED & Screening Committee

Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull's Eye ...........................................................................................................e21
Laura Moonen, MSc, Jules L. Derks, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, and Ernst Jan M. Speel, PhD

(continued on next page)
TABLE OF CONTENTS (continued)

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works: Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage: Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions: For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Author rights: Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorrights).

Notice: The statements and opinions contained in the material herein are solely those of the individual authors and contributors and not those of the International Association for the Study of Lung Cancer or Elsevier Inc. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher or the IASLC for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, please contact Derrick Imasa, Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, New York, NY 10169; phone (212) 633-3874; fax (212) 462-1935; e-mail: reprints@elsevier.com.

For advertising orders and inquiries: North and South America: Courtney Leonard, Elsevier Inc., 230 Park Avenue, New York, NY 10169; phone (732) 779-3368; e-mail: c.leonard@elsevier.com. Europe/ROW: Robert Bayliss, Elsevier Inc., 125 London Wall, London, EC2Y 5AN, UK; phone (+44) (20) 7424 4454; e-mail: r.bayliss@elsevier.com.

Journal of Thoracic Oncology is indexed in Current Contents/Clinical Medicine, Science Citation Index Expanded (SCIE), Journal Citation Reports/Science Edition, and MEDLINE.